Immunodiagnostic Systems Hldgs PLC SARS-CoV-2 manufacturing agreement (2511X)
August 27 2020 - 2:00AM
UK Regulatory
TIDMIDH
RNS Number : 2511X
Immunodiagnostic Systems Hldgs PLC
27 August 2020
Immunodiagnostic Systems Holdings plc.
27 August 2020
SARS-CoV-2 manufacturing agreement with The Binding Site
Immunodiagnostic Systems Holdings plc (IDS), a specialty
solution provider to the clinical laboratory diagnostic market, is
pleased to announce that it will provide contract manufacturing
services to The Binding Site (TBS) related to their SARS-CoV-2
Antibody ELISA test, which was launched in Europe and other markets
which accept the CE mark today. The test has also been submitted
for rapid FDA approval.
The antibody coated ELISA microtiter plates for this test will
be produced at the IDS facility in Boldon, UK, where IDS has the
capacity to provide up to two million tests per month for TBS. The
process involves coating the microtiter plates with the trimeric
spike protein developed by TBS and the University of Birmingham
(UoB). The plates are then washed and stabilized using proprietary
IDS reagents.
About the TBS SARS-COV-2 ELISA test
The SARS-CoV-2 Antibody ELISA assay was developed by TBS and
UoB, based on an initial antigen provided by the University of
Southampton, with a focus on mild, non-hospitalised patient blood
samples. The new test specifically detects antibodies to the
SARS-CoV-2 trimeric spike protein, which is an important protein
for the virus infectivity. Targeting IgG, IgA and IgM antibodies,
the assay will cover all the immunoglobulins which are vital in the
body's fight against this virus. These three antibodies appear at
different times after infection. The test was designed to detect
all three, to increase detection at the earliest possible stage
after exposure to the virus. The CE-marked ELISA test is simple to
use and provides up to 93 test results in 60-90 minutes.
Jaap Stuut, CEO of IDS commented:
"We are delighted that TBS chose IDS to be their manufacturing
partner for this unique SARS-CoV-2 ELISA assay. Leveraging our
30-year experience in producing ELISA tests, we worked with the
team at TBS to agree, validate and audit the manufacturing
processes in record time. We look forward to supporting TBS through
the commercialisation of this project"
Charles de Rohan, CEO of TBS commented:
"We are very excited to bring this antibody test to market. It
is really important that we are able to meet the potentially high
market demand, and we chose IDS as our manufacturing partner to
increase capacity and bring more product to market in such a short
time. Collaboration is one pillar of our company values and we are
delighted, once again, to work closely with one of the best in the
business."
About IDS
IDS is a specialist in-vitro diagnostic provider to the clinical
laboratory market. IDS develops, manufactures and markets
innovative immunoassays and automated immuno-analyser technologies
to provide improved diagnostic outcomes for patients. IDS can
provide outsourced manufacturing services covering all areas of
ELISA / RIA assay manufacture, for clinical and research use.
IDS is headquartered in Boldon, UK, and listed on the
Alternative Investment Market of the London Stock Exchange.
About TBS
Founded in 1986 by a group of former researchers based at UOB,
The Binding Site (www.bindingsite.com) is today recognised as a
market leader in the development of products for the investigation
of a range of disorders involving immunodeficiency. Its product
range covers immunoglobulins, subclasses, vaccine response and
complement. The Binding Site has a direct presence in over 25
countries and product sales through business partners in more than
100 countries.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 6111
Jaap Stuut, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFLFSETEIRFII
(END) Dow Jones Newswires
August 27, 2020 02:00 ET (06:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jul 2023 to Jul 2024